Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders.

Abstract

Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.

• Authors: Moshe Rogosnitzky, Rachel Danks, Elena Kardash
• Journal: Anticancer research (Anticancer Res) Vol. 32 Issue 7 Pg. 2471-8 (Jul 2012) ISSN: 1791-7530 [Electronic] Greece
• PMID: 22753703 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Anti-Allergic Agents
• Antineoplastic Agents
• ortho-Aminobenzoates
• tranilast

Topics

• Adult
• Animals
• Anti-Allergic Agents (pharmacology)
• Antineoplastic Agents (pharmacology, therapeutic use)
• Cell Line, Tumor
• Clinical Trials as Topic
• Female
• Humans
• Neoplasms (drug therapy)
• ortho-Aminobenzoates (pharmacology, therapeutic use)